ERX Pharmaceuticals is led by executives with deep experience in emerging life science companies, as well as specific experience in treatments for obesity and metabolic diseases.
Teo Uysal, M.B.A. – President and CEO
Mr. Uysal is a co-founder of ERX Pharmaceuticals and has been President, Chief Executive Officer, and a director of the Company since its inception. With a career spanning two decades, he is an experienced scientist, entrepreneur, executive, and venture capitalist across diverse technology sectors.
Prior to ERX, he was the Director of New Ventures and Entrepreneurship at King Abdullah University of Science and Technology in Saudi Arabia where he oversaw three programs providing capital and advisory support to entrepreneurs forming new companies based on innovative technologies – Entrepreneurship Center, Seed Fund, and Early Stage Fund. Prior to that he was also a co-founder and former President and Chief Executive Officer of Syndexa Pharmaceuticals, a Boston-based metabolic diseases therapeutics company.
Mr. Uysal has worked in various capacities in the life sciences and pharmaceutical sectors at PwC/PRTM, Precision Therapeutics, Inc., and Polaris Venture Partners. He started his professional life as a scientist at Harvard University, where he conducted biomedical research in the field of metabolic diseases and co-authored 17 original research articles. He holds an M.B.A. from Carnegie Mellon Tepper School of Business and a B.A. from Brandeis University. He also attended Harvard Medical School and Harvard University where he successfully completed various advanced biomedical courses.
Jonathan Lieber, M.B.A. – Chief Financial Officer
Mr. Lieber joined ERX Pharmaceuticals in April 2019 as Chief Financial Officer and is a seasoned financial executive with more than 20 years of experience in financial and executive management at emerging growth life sciences companies and in investment banking. He also currently serves as a Managing Director at Danforth Advisors, a company providing integrated finance, accounting, and human resource solutions to healthcare companies. Mr. Lieber most recently served as the Chief Financial Officer of Histogenics Corporation, a publicly-held cell therapy company focused on the musculoskeletal segment of the market.
Prior to Histogenics, Mr. Lieber served as the Chief Financial Officer of Metamark Genetics, Inc., a privately held, urology-focused, molecular diagnostics company, as the Chief Financial Officer and Treasurer of Repligen Corporation, a publicly held manufacturer and supplier of high-value consumables to the life sciences industry, and the Chief Financial Officer of Xcellerex Inc. (acquired by GE Healthcare), a company engaged in the manufacture and sale of capital equipment and related consumables to the life sciences industry. Previously, Mr. Lieber served as the Chief Financial Officer of Altus Pharmaceuticals where he led all public and private capital raising activities at the company, including its $110 million initial public offering and a subsequent $90 million follow-on offering.
Prior to joining Altus, Mr. Lieber was an investment banker for 10 years where he originated and executed on numerous corporate financings and merger and acquisition transactions at SG Cowen and Salomon Brothers Inc. He received a B.S. in business administration and finance from Boston University and an M.B.A. in finance from New York University Stern School of Business.